brought to you by guest. Protected by copyright.
KD is currently unknown, according to the available literature and our experiences, it is important to point out that therapy for KD also leads to the resolution of lung problems and findings.

ASSOCIATION BETWEEN GASTROINTESTINAL MANIFESTATIONS AND THE RISK OF RENAL DISEASE IN CHILDREN WITH IGA VASCULITIS

Methods This retrospective study included children with IgAV with IgAV and GI manifestations. The aim of the research was to analyze clinical and biochemical parameters in patients with IgAV and GI manifestations.

Results Out of 611 children with IgAV, 320 were males and 291 were females. The overall GI symptoms prevalence was 45.9% and the median (range) age at diagnosis was 6.42 (4.5-8.83) years. Among patients with GI symptoms there were 1.44 times more males (N=166) than females (N=115), which was statistically significant (p=0.003). Patients with GI symptoms had less infections before the appearance of purpura (59.8% vs. 70.9%, p=0.005) and upper extremities (35.2% vs. 24.7%, p=0.006), as well as generalized rash (38.8% vs. 28.3%, p=0.008). These patients also had significantly higher values of C-reactive protein, leukocyte count, erythrocytes and platelets, hemoglobin, hematocrit and D-dimer concentrations and lower levels of IgG and IgM. In our cohort 42 out of 281 children (14.9%) had the most severe GI manifestations (intussusception and/or massive bleeding) with significantly higher values of 24-hour urine protein levels and D-dimer concentrations and lower total serum protein, albumin, IgG, IgM and C3 levels in comparison with children whose GI manifestations were not severe. Predictors of severe GI involvement were: relapse of the disease, generalized rash, rash extended on upper extremities, rash extended to the face, recurrent rash and renal involvement, as well as lower values of prothrombin time, fibrinogen and IgM among the laboratory parameters. Patients with GI symptoms were 1.68 times more likely to develop nephritis, and this probability was 2.58 times higher if GI symptoms occurred before other symptoms. Other predictors of nephritis were: severe and moderate GI manifestations, recurrent rash, one or more relapses of IgAV, and older age.

Conclusion Older children with IgAV and severe GI manifestations in whom IgAV began with GI symptoms had a higher risk of acute and chronic complications of the disease.

SUPPORT: Croatian Science Foundation project IP-2019-04-8822

ASSOCIATED UVEITIS PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS-THERAPY ON THE INTRAOCULAR INFLAMMATION AND THE NEED FOR TOPICAL GLUCOCORTICOID THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS-ASSOCIATED UVEITIS

Methods We have conducted a longitudinal observational study with JIA-U patients in whom systemic immunomodulatory treatment (IMT: biologics and/or MTX) was introduced and who were followed at least 3 months in the period between 2011 and 2017. The data about the number of cells in the anterior chamber (AC) according to Standardization of Uveitis Nomenclature (SUN) Working Group criteria, related to TGC, systemic therapy and JIA complications were collected during each examination. Generalized linear mixed models were used to analyze the relationships between treatment with biologics, MTX, TGC and the grade of inflammation in AC according to SUN criteria.

Results 38 JIA-U patients (69 eyes) with median (range) age of 4.9 (2-15) years and follow up period of 209 (19-381) weeks were included. There were a total of 1205 examinations. At the first examination JIA-U was detected in 16 (42.1%) of patients, 59 (79.7%) of the eyes had ≤1+ cells in the AC, and in 19 (50%) of JIA-U patients complications were already present. MTX was introduced in 23 (60.5%) JIA-U patients before the initiation of the study. 8 (21%) had already received biologics, while in 4 (10.5%) prior systemic glucocorticoids were also used. Before the completion of the study, all patients received MTX and 40% JIA-U were treated with biologics. The average number of TGC doses decreased from 3.74 at baseline to 0.72 in the 48th month. After Friedman and the post hoc test a significant difference in the daily doses of TGC could be seen from the 12th month after application of systemic IMT. The number of daily doses of TGC as well as the degree of inflammation in AC per eye decreased over time. Using generalized linear mixed models it was shown that the treatment with biologics, but not with MTX and systemic glucocorticoids, was associated with lower